{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:16Z","timestamp":1786991476409,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A2025286"],"award-info":[{"award-number":["2018R1A5A2025286"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021M3E5E7024855"],"award-info":[{"award-number":["2021M3E5E7024855"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6C101A442"],"award-info":[{"award-number":["2021R1A6C101A442"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jare.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T18:18:20Z","timestamp":1660155500000},"page":"173-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers"],"prefix":"10.1016","volume":"47","author":[{"given":"Soo-Yeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seojeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunji","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Hee Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seojeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Reum","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanju","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Yeon Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonari","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghwa","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jare.2022.08.003_b0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/1568026618666180531092503","article-title":"Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions","volume":"18","author":"Bojadzic","year":"2018","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1016\/j.jare.2022.08.003_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"1-2","key":"10.1016\/j.jare.2022.08.003_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.crci.2015.12.004","article-title":"Targeting protein\u2013protein interactions, a wide open field for drug design","volume":"19","author":"Bakail","year":"2016","journal-title":"C R Chim"},{"issue":"9","key":"10.1016\/j.jare.2022.08.003_b0020","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161212799436412","article-title":"Computational prediction of protein hot spot residues","volume":"18","author":"Kenneth Morrow","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.jare.2022.08.003_b0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1097-2765(03)00350-2","article-title":"An open-and-shut case? Recent insights into the activation of EGF\/ErbB receptors","volume":"12","author":"Burgess","year":"2003","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jare.2022.08.003_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/erc.0.0080011","article-title":"The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification","volume":"8","author":"Prenzel","year":"2001","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.jare.2022.08.003_b0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"The New England journal of medicine"},{"issue":"19","key":"10.1016\/j.jare.2022.08.003_b0040","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: An update","volume":"22","author":"Abrahao-Machado","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jare.2022.08.003_b0045","unstructured":"NCCN. NCCN GUIDELINES FOR PATIENTS\u00ae. Available at: https:\/\/wwwnccnorg\/patients\/guidelines\/content\/PDF\/stomach-patientpdf. 2019."},{"issue":"4","key":"10.1016\/j.jare.2022.08.003_b0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"4905","key":"10.1016\/j.jare.2022.08.003_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science (New York, NY)"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2559.2001.01084.x","article-title":"Overexpression of HER2\/neu in solid tumours: an immunohistochemical survey","volume":"38","author":"Koeppen","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.jare.2022.08.003_b0065","first-page":"27","article-title":"Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer. European journal of cancer (Oxford","volume":"55","author":"Cresti","year":"2016","journal-title":"England"},{"issue":"1","key":"10.1016\/j.jare.2022.08.003_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2012.06.004","article-title":"A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2","volume":"325","author":"Kim","year":"2012","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejps.2013.06.014","article-title":"Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells","volume":"50","author":"Nam","year":"2013","journal-title":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.jare.2022.08.003_b0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4062\/biomolther.2016.168","article-title":"Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90","volume":"24","author":"Jun","year":"2016","journal-title":"Biomol Ther (Seoul)"},{"issue":"13","key":"10.1016\/j.jare.2022.08.003_b0085","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.onc.1200978","article-title":"ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis","volume":"14","author":"Chang","year":"1997","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.jare.2022.08.003_b0090","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1021\/ja0292703","article-title":"A Gene-Expression Inhibitor that Targets an \u03b1-Helix-Mediated Protein Interaction","volume":"125","author":"Asada","year":"2003","journal-title":"J Am Chem Soc"},{"issue":"4","key":"10.1016\/j.jare.2022.08.003_b0095","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/10826068.2012.738273","article-title":"Expression and purification of a soluble ESX-binding core domain of SUR2","volume":"43","author":"Jeon","year":"2013","journal-title":"Prep Biochem Biotech"},{"issue":"9","key":"10.1016\/j.jare.2022.08.003_b0100","first-page":"2531","article-title":"Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence","volume":"5","author":"Segovia-Mendoza","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2022.08.003_b0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat Protoc"},{"issue":"20","key":"10.1016\/j.jare.2022.08.003_b0110","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.202162199","article-title":"External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator","volume":"99","author":"Asada","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jare.2022.08.003_b0115","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/ja038855+","article-title":"A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction","volume":"126","author":"Shimogawa","year":"2004","journal-title":"J Am Chem Soc"},{"issue":"22","key":"10.1016\/j.jare.2022.08.003_b0120","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","article-title":"Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges","volume":"36","author":"Gasteiger","year":"1980","journal-title":"Tetrahedron"},{"issue":"14","key":"10.1016\/j.jare.2022.08.003_b0125","first-page":"1710","article-title":"Molecular complexes at a glance: automated generation of two-dimensional complex diagrams","volume":"22","author":"Stierand","year":"2006","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"6","key":"10.1016\/j.jare.2022.08.003_b0130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.jare.2022.08.003_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05967-y","article-title":"Crystal structure of human Mediator subunit MED23","volume":"9","author":"Mont\u00e9","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jare.2022.08.003_b0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/prot.25219","article-title":"New additions to the ClusPro server motivated by CAPRI","volume":"85","author":"Vajda","year":"2017","journal-title":"Proteins"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nprot.2016.169","article-title":"The ClusPro web server for protein-protein docking","volume":"12","author":"Kozakov","year":"2017","journal-title":"Nat Protoc"},{"issue":"5568","key":"10.1016\/j.jare.2022.08.003_b0150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1126\/science.1068943","article-title":"Transcription Control by E1A and MAP Kinase Pathway via Sur2 Mediator Subunit","volume":"296","author":"Stevens","year":"2002","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jare.2022.08.003_b0155","doi-asserted-by":"crossref","unstructured":"Griffiths SJ, Koegl M, Boutell C, Zenner HL, Crump CM, Pica F, et al. A systematic analysis of host factors reveals a Med23-interferon-\u03bb regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog. 2013;9(8):e1003514.","DOI":"10.1371\/journal.ppat.1003514"},{"issue":"25","key":"10.1016\/j.jare.2022.08.003_b0160","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/sj.onc.1210379","article-title":"Trastuzumab: triumphs and tribulations","volume":"26","author":"Nahta","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.jare.2022.08.003_b0165","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s11538-011-9663-3","article-title":"A mathematical model for the effects of HER2 over-expression on cell cycle progression in breast cancer","volume":"73","author":"Eladdadi","year":"2011","journal-title":"Bull Math Biol"},{"issue":"5","key":"10.1016\/j.jare.2022.08.003_b0170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1756283X12450246","article-title":"Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer","volume":"5","author":"Okines","year":"2012","journal-title":"Therapeutic advances in gastroenterology"},{"issue":"6","key":"10.1016\/j.jare.2022.08.003_b0175","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers12061540","article-title":"Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance","volume":"12","author":"Hwang","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.jare.2022.08.003_b0180","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41416-020-01255-z","article-title":"Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice","volume":"124","author":"Waller","year":"2021","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jare.2022.08.003_b0185","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1101\/gad.14.9.1027","article-title":"Protein\u2013protein interactions define specificity in signal transduction","volume":"14","author":"Pawson","year":"2000","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.jare.2022.08.003_b0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd3680","article-title":"Protein-protein interaction inhibitors get into the groove","volume":"11","author":"Mullard","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"Pt 1","key":"10.1016\/j.jare.2022.08.003_b0195","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/bj20021238","article-title":"Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression","volume":"370","author":"Vernimmen","year":"2003","journal-title":"Biochem J"},{"issue":"8","key":"10.1016\/j.jare.2022.08.003_b0200","first-page":"2269","article-title":"Positive and negative regulatory elements in the human erbB-2 gene promoter","volume":"9","author":"Chen","year":"1994","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jare.2022.08.003_b0205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.suronc.2015.05.004","article-title":"High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients","volume":"24","author":"Jiang","year":"2015","journal-title":"Surg Oncol"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbrc.2006.04.153","article-title":"A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells","volume":"345","author":"Qian","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.jare.2022.08.003_b0215","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/cas.14006","article-title":"Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer","volume":"110","author":"Kuwano","year":"2019","journal-title":"Cancer Sci"},{"issue":"24","key":"10.1016\/j.jare.2022.08.003_b0220","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1128\/MCB.00866-07","article-title":"An EGR2\/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer","volume":"27","author":"Dillon","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.jare.2022.08.003_b0225","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/cas.13081","article-title":"CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance","volume":"107","author":"Minemura","year":"2016","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.jare.2022.08.003_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2461","article-title":"Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification","volume":"11","author":"Powe","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.jare.2022.08.003_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101444","article-title":"Hybrid (18)F-FDG-PET\/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study","volume":"11","author":"Schiano","year":"2019","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.jare.2022.08.003_b0240","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1038\/sj.onc.1205503","article-title":"ErbB2 activation of ESX gene expression","volume":"21","author":"Neve","year":"2002","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/104454903321515896","article-title":"The epithelial-specific ETS transcription factor ESX\/ESE-1\/Elf-3 modulates breast cancer-associated gene expression","volume":"22","author":"Eckel","year":"2003","journal-title":"DNA Cell Biol"},{"issue":"3","key":"10.1016\/j.jare.2022.08.003_b0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0265","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.celrep.2013.09.009","article-title":"Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers","volume":"5","author":"Mungamuri","year":"2013","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.jare.2022.08.003_b0270","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/onc.2017.382","article-title":"A novel HER2 gene body enhancer contributes to HER2 expression","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jare.2022.08.003_b0275","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bjc.1995.146","article-title":"Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma","volume":"71","author":"Hollywood","year":"1995","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jare.2022.08.003_b0280","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/bi980981g","article-title":"Inhibition of transcription elongation in the HER-2\/neu coding sequence by triplex-directed covalent modification of the template strand","volume":"38","author":"Ebbinghaus","year":"1999","journal-title":"Biochemistry"},{"issue":"32","key":"10.1016\/j.jare.2022.08.003_b0285","doi-asserted-by":"crossref","first-page":"24246","DOI":"10.1074\/jbc.M000820200","article-title":"Targeting the ets binding site of the HER2\/neu promoter with pyrrole-imidazole polyamides","volume":"275","author":"Chiang","year":"2000","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"10.1016\/j.jare.2022.08.003_b0290","article-title":"Modeling ErbB2-p130Cas interaction to design new potential anticancer agents","volume":"9","author":"Costamagna","year":"2019","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.jare.2022.08.003_b0295","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1016\/j.bmcl.2009.08.090","article-title":"Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.jare.2022.08.003_b0300","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/cas.13715","article-title":"Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl(-) \/H(+) transporter inhibition in human breast cancer cells","volume":"109","author":"Fujimoto","year":"2018","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.jare.2022.08.003_b0305","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.jare.2022.08.003_b0310","unstructured":"FDA approves pralsetinib for lung cancer with RET gene fusions [press release]. September, 04 2020."},{"key":"10.1016\/j.jare.2022.08.003_b0315","doi-asserted-by":"crossref","unstructured":"Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res. 2016;22(4):1000-10.","DOI":"10.1158\/1078-0432.CCR-14-3156"},{"key":"10.1016\/j.jare.2022.08.003_b0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cbpa.2018.06.004","article-title":"Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area","volume":"44","author":"Ran","year":"2018","journal-title":"Curr Opin Chem Biol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123222001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123222001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:51:48Z","timestamp":1778835108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123222001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":62,"alternative-id":["S2090123222001710"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2022.08.003","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}